Table 2.

Sclerostin in patients suffering from polymyalgia rhematica (PMR) taking GC.

Characteristics		Controls	Cases	P valuea
Disease	PMR	21	21
Sex, n	Male	11	11	1.00
	Female	10	10
Age, years		74.0 (72.0–76.0)	73.0 (72.0–75.0)	0.99
Current smokers, n		0	0	1.00
BMI, kg/m2		27.5 (24.4–28.6)	28.1 (24.8–29.3)	0.95
BMI categories, n	<25 kg/m2	6	6	1.00
	≥25–29 kg/m2	12	12
	≥30 kg/m2	3	3
MTX, n			2
CRP, mg/L			5.9 (2.05–14.75)
cGC dose, mg			3300 (1850–8150)
Actual GC dose at sampling, mg			3.0 (2–9.75)
Patients taking GC at sampling, n			20
Disease duration, years			1.31 (0.42–4.22)
Bone status, n	Osteoporosis (T-score <−2.5) Osteopenia (T-score −1.0 to −2.5) Not reported		2 7 4
Sclerostin, pmol/L		70.6 (59.8–85.9)	51.9 (40.0–59.2)	<0.01
PINP, ng/mL		31.2 (21.8–61.2)	30.2 (19.8–43.8)	0.47
Osteocalcin, ng/mL		16.3 (10.1–26.7)	10.7 (5.5–15.1)	<0.02
CTX, ng/mL		0.30 (0.17–0.53)	0.18 (0.05–0.23)	<0.04

For nominal variables n (%), for continuous variables median (1st–3rd quartile) are given.

^aChi-square test for nominal variables and Kruskal–Wallis test for continuous variables.

BMI, body mass index; CDAI, clinical disease activity score; cGC, cumulative Glucocorticoid dose; CRP, C-reactive Protein; CTX, carboxy-terminal telopeptide of type I collagen; GC, Glucocorticoid; MTX, Methotrexate; P1NP, intact amino-terminal propeptide of type I procollagen; PMR, polymyalgia rheumatica.